Evidence map›Paper›PMID 19818769›Full record

ArticleExperimental cell research2009

Necdin and TrkA contribute to modulation by p75NTR of resistance to oxidant stress.

Christopher A Ingraham, Nina F Schor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental cell research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. p75NTR: an enhancer of fenretinide toxicity in neuroblastoma.Cancer chemotherapy and pharmacology · 2013
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Christopher A IngrahamDepartment of Pediatrics, University of Rochester Medical Center, Rochester, NY 14642, USA.
Nina F Schor
University of Rochester Medical Center · US

Funding

NEUROTROPHIC MECHANISMS IN NEUROBLASTOMAR01NS038569 · NINDS · UNIVERSITY OF ROCHESTER · PI SCHOR, NINA F · 2000 to 2008
$2.4M
TARGETED THERAPY FOR CHEMORESISTANT TUMORSR01CA074289 · NCI · UNIVERSITY OF ROCHESTER · PI SCHOR, NINA F · 1998 to 2006
$1.6M
NCI NIH HHS R01 CA074289NINDS NIH HHS NS038569NINDS NIH HHS R01 NS038569
6 · The paper itself

Abstract

The neurotrophin receptor p75NTR provides protection from oxidant stress induced by 6-hydroxydopamine (6-OHDA) and resultant cell death. In the absence of p75NTR, TrkA is upregulated and its signaling pathway effectors are increasingly activated. Necdin, a MAGE protein and known interactor of p75NTR and TrkA, is a potential mediator of this phenomenon. Decreased expression of necdin protein in p75NTR-deficient PC12 cells decreased TrkA expression and increased PC12 cell resistance to 6-OHDA. Inhibition of JNK phosphorylation by SP600125 also resulted in increased resistance to 6-OHDA, suggesting that TrkA signaling underlies the susceptibility of these cells to oxidant stress.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsbcl-2-Associated X ProteinBH3 Interacting Domain Death Agonist ProteinCaspase 3Cell DeathCell SurvivalExtracellular Signal-Regulated MAP KinasesGene ExpressionMAP Kinase Kinase 4Nerve Tissue ProteinsNuclear ProteinsOxidative StressOxidopaminePC12 CellsPhosphorylationAdaptor Proteins, Signal TransducingBax protein, ratbcl-2-Associated X ProteinBH3 Interacting Domain Death Agonist ProteinBid protein, ratCasp3 protein, ratCaspase 3Extracellular Signal-Regulated MAP KinasesMAP Kinase Kinase 4necdinNerve Tissue ProteinsNgfr protein, ratNuclear ProteinsOxidopamineProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2Receptors, Growth FactorReceptors, Nerve Growth FactorReceptor, trkARNA, Small Interfering

Identifiers

PMID19818769
PMCPMC2788019
OpenAlexW2079675193

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.